Immune checkpoint inhibitors (ICIs), including agents targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) pathways, have transformed the treatment landscape of several cancers [5]. Here, PDCD1 is linked to cancer.